摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-Phenylethyl)-1,3,2lambda~5~-oxazaphosphinan-2-one | 391640-22-5

中文名称
——
中文别名
——
英文名称
2-(2-Phenylethyl)-1,3,2lambda~5~-oxazaphosphinan-2-one
英文别名
2-(2-phenylethyl)-1,3,2λ5-oxazaphosphinane 2-oxide
2-(2-Phenylethyl)-1,3,2lambda~5~-oxazaphosphinan-2-one化学式
CAS
391640-22-5
化学式
C11H16NO2P
mdl
——
分子量
225.22
InChiKey
ADGQJISXYKPKHW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Matrix metalloproteinase inhibitors
    申请人:——
    公开号:US20020103166A1
    公开(公告)日:2002-08-01
    A compound of the general formula I 1 wherein Y is O or S; n is 1, 2, 3 or 4; X represents hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group; R1 is 2 wherein E, when present represents, a bond or optionally substituted methylene or ethylene; s and t are independently 0, 1, 2 or 3; A and A′ independently represent a bond, or a saturated or unsaturated, optionally substituted cyclic or heterocyclic hydrocarbon di- or triradical; Z represents a bond, O, S, C(O), C(O)NR7, NR7C(O) or NR7, wherein R7 is hydrogen, hydroxy, branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical; R5 represents a bond, alkane or alkene diradical, one or more ether diradicals (R—O—R′) or amine diradicals (R—N—R′), wherein R and R′ independently represent alkane or alkene diradicals with a C-content from 0 to 3; R6 represents hydrogen, hydroxy, halogen, cyano, nitro, branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical, unsaturated optionally substituted cyclic or heterocyclic hydrocarbon radical, NR8R9, C(O)NR8R9, C(O)R8, CO(O)R8, S(O) 2 R9, wherein each R8 and R9 independently represent hydrogen, halogen, a branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical; R2 represents hydrogen, (C 1-8 )alkyl, (C 2-6 )alkenyl, (C 3-8 )cycloalkyl, aryl(C 0-6 )alkyl or heteroaryl(C 0-6 )alkyl; provided that if A, A′, Z and R5 are all bonds, and s and t are both 0 (zero), then R6 is different from hydrogen; or a salt, hydrate or solvate thereof. The compounds are valuable for human and veterinary therapy.
    一般式为I1的化合物,其中Y为O或S;n为1、2、3或4;X代表羟肟酸、羧酸、膦酸、乙酰硫甲基基团或巯基甲基基团;R1为2,其中E在存在时表示键或可选取代的亚甲基或乙烯基;s和t分别为0、1、2或3;A和A′分别表示键或饱和或不饱和、可选取代的环烷基或杂环烷基二元或三元基团;Z表示键、O、S、C(O)、C(O)NR7、NR7C(O)或NR7,其中R7为氢、羟基、支链或直链、饱和或不饱和、可选取代的碳氢基团;R5表示键、烷基或烯基二元基团、一个或多个醚二元基团(R—O—R′)或胺二元基团(R—N—R′),其中R和R′分别独立地表示具有0至3个碳的烷基或烯基二元基团;R6表示氢、羟基、卤素、氰基、硝基、支链或直链、饱和或不饱和、可选取代的碳氢基团、不饱和可选取代的环烷基或杂环烷基基团、NR8R9、C(O)NR8R9、C(O)R8、CO(O)R8、S(O)2R9,其中每个R8和R9独立地表示氢、卤素、支链或直链、饱和或不饱和、可选取代的碳氢基团;R2表示氢、(C1-8)烷基、(C2-6)烯基、(C3-8)环烷基、芳基(C0-6)烷基或杂环芳基(C0-6)烷基;前提是如果A、A′、Z和R5都是键,并且s和t都为0(零),则R6与氢不同;或其盐、水合物或溶剂化物。这些化合物对人类和兽医疗法有价值。
  • MATRIX METALLOPROTEINASE INHIBITORS
    申请人:Leo Pharma A/S
    公开号:EP1303527A1
    公开(公告)日:2003-04-23
  • US6521606B2
    申请人:——
    公开号:US6521606B2
    公开(公告)日:2003-02-18
  • [EN] MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICIELLES
    申请人:LEO PHARM PROD LTD
    公开号:WO2002006293A1
    公开(公告)日:2002-01-24
    A compound of the general formula (I) wherein Y is O or S; n is 1, 2, 3 or 4; X represents hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group; R2 represents hydrogen, (C1-8)alkyl, (C2-6)alkenyl, (C3-8)cycloalkyl, aryl(C0-6)alkyl or heteroaryl(C0-6)alkyl; provided that if A, A', Z and R5 are all bonds, and s and t are both 0 (zero), then R6 is different from hydrogen; or a salt, hydrate or solvate thereof. The compounds are valuable for human and veterinary therapy.
查看更多

同类化合物

曲磷胺 曲磷胺 异环磷酰胺杂质F 异环磷酰胺 [(2-羟基-2-氧代-1,4,2-氧氮杂磷杂环己烷-4-基)甲基]膦酸 4-过氧化氢异环磷酰胺 4-氧代异环磷酰胺 4-乙基-7-甲基-7-氮杂-2,6-二氧杂-1-磷杂双环[2.2.2]辛烷1-硫化物 2’-氧代异环磷酰胺 2-[2-氯乙基-[3-(2-氯乙基)-2-氧代-1-氧杂-3-氮杂-2-磷杂环己-2-基]氨基]乙基甲烷磺酸酯 2,3,4,6,7,8-六氢-[1,3,2]氧氮杂膦咛并[2,3-b][1,3,2]氧氮杂膦咛 (2-氯-乙基)-[(R)-3-(2-氯-乙基)-2-氧代-2lambda5-[1,3,2]氧氮杂磷杂环己烷-2-基]-胺 (2R*,4aS*,8aR*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aR*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2R*,4aS*,8aS*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aS*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (S,S)-2-oxo-2-propionyl-1,3,2-oxaphosphorinane 2-(Dimethylamino)-3-phenyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3,5,5-trimethyl-1,3,2-oxazaphosphorinane cis-2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-5-tert-butyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-phenyl-1,3,2-oxazaphosphorinane 3,3,5,5-tetramethyl-2-oxido-2-oxo-1,4,2-oxaazaphosphorinane 2-(2-chloroethylamino)-3-(1-methyl-2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 4-ethyl-2-hydroxy-2-oxo-tetrahydro-4H-1,4,2-oxazaphosphorine geranyloxyifosfamide 4-methoxy-ifosfamide (2-chloroethyl)-[3-(2-chloroethyl)-2-oxo-4-pentyloxy-2λ5-[1,3,2]oxazaphosphinan-2-yl]amine 3-ethyl-2-hydroxy-2-oxo-1,4,2-oxazaphosphorinane Methyl-[3-(3-methyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine 2-Oxo-3-(propan-2-yl)-1,3,2-oxazaphosphinan-2-ium 3-(2-Chloroethyl)-2-(2-chloroethyl)amino-4-hydroxytetrahydro-2H-1,3,2-oxazaphosphorine 3-(2-Chloroethyl)-2-(1-ethyl-2-mesyloxyethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,5-dimethyl-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,4-dimethyl-, 2-oxide (3-Isopropyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-acetic acid methyl ester cis-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane trans-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane (2S,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2S,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (S)-(2l,6l)-2-(methoxymethyl)-6-methyl-3-(1-methylethyl)-1,3,2-oxazaphosphorinane 2-sulfide (S)-1-((2S,6S)-3-tert-Butyl-6-methyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-3-methyl-hex-5-en-2-one 2-methoxy-1,3,2-oxazaphosphinane 3-(2-Chloroethyl-2-<(2-chloroethyl)-(3-mesyloxytrimethylen)-amino>-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2-chloro-3-[(S)-α-methylbenzyl]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide (S)-(2u,6l)-3-(1,1-Diethylpropyl)-6-methyl-2-(2-propenyl)-1,3,2-oxazaphosphorinane 2-oxide 3-(2-chloro-ethyl)-2-(2-hydroxy-ethylamino)-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-one isopropyl-[3-(3-isopropyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine